Form 8-K - Current report:
SEC Accession No. 0001636282-26-000098
Filing Date
2026-08-04
Accepted
2026-08-04 16:05:45
Documents
13
Period of Report
2026-08-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K syre-20260804.htm   iXBRL 8-K 29724
2 EX-99.1 spyre-20260630xexx991.htm EX-99.1 113722
6 image_1.jpg GRAPHIC 8180
  Complete submission text file 0001636282-26-000098.txt   290669

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT syre-20260804.xsd EX-101.SCH 1777
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT syre-20260804_lab.xml EX-101.LAB 23727
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT syre-20260804_pre.xml EX-101.PRE 13784
16 EXTRACTED XBRL INSTANCE DOCUMENT syre-20260804_htm.xml XML 2927
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 261238560
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)